2006
Company incorporated and signed first deal.
2007
- Opened Abex Technical Office in Pretoria.
- Anita Smal joined as Regulatory Affairs Director in Sep 2007.
2008
- First applications for registration submitted through our subsidiary, Lasara Traders.
- Signed strategic consulting deal with Clicks Group to establish Unicorn.
2009
- Formed Nucare in partnership with Carecross Health and developed first integrated e-scripting program in RSA.
- Opened office in Shanghai, China.
- Lasara Traders obtains its licence to manufacture and import medicines from the MCC.
2010
- First MA registered (Nebivolol) and licensed out
- Established as professional partner of EXTEDO to provide Software Solutions for eCTD and pharmacovigilance in South Africa.
- Incorporated strategic JV in Australia and New Zealand and won first major tender bid overseas.
2011
Established JV trading partnership into certain South East Asian markets
2012
- One of the first Quetiapine generics launched in South Africa.
- Second to market with Sildenafil.
- First major tender buyout awarded by DoH.
2014
First eCTD MA approved in South Africa by MCC for a generic medicine (Esomeprazole).
2015
Milestone of more than 100 approved SKUs.
2016
- Signed Strategic Distribution Agreement with Clicks (Unicorn) Pharmacies.
- First biosimilar Enoxaparin approved in EU and licensed out.
2017
- Opened office in Cyprus and United Kingdom.
- Established ABEX Consumer Division and signed exclusive rights to commercialize Nasaleze in SA.
2018
- Established strategic JV in UK for pan EU sales footprint and RnD cooperation
- First MA approved in UK (Gabapentin)
- Acquired Eden Pharmaceuticals Pvt Ltd in Australia
2019
- Launched five non-prescription Consumer Health brands into SA market.
- Signed exclusive partnership with Enzymatica for the commercialization of ColdZyme in Australia and New Zealand.